IMMUNOBIOLOGY Brief report A novel proteoliposomal vaccine elicits potent antitumor immunity in mice

Therapeutic vaccination against idiotype is a promising strategy for immuno-therapy of B-cell malignancies. Its feasibil-ity, however, is limited by the requirement for a patient-specific product. Here we describe a novel vaccine formulation pre-pared by simply extracting cell-mem-brane proteins from lymphoma cells and incorporating them together with IL-2 into proteoliposomes. The vaccine was pro-duced in 24 hours, compared with more labor-intensive and time-consuming hy-bridoma or recombinant DNA methods. The vaccine elicited T-cell immunity in vivo, as demonstrated by secretion of type 1 cytokines. It protected against tu-mor challenge at doses of tumor antigen 50 to 100 times lower than that previously observed using either liposomes formu-lated with IL-2 and secreted lymphoma immunoglobulin or a prototype vaccine consisting of lymphoma immunoglobulin conjugated to keyhole limpet hemocya-nin. The increased potency justifies test-ing similar patient-specific human vac-cines prepared using extracts from primary tumor samples. (Blood. 2007